Key Professional Analysts at H.C. Wainwright Reiterate their ‘Buy’ rating for Caladrius Biosciences (NASDAQ:CLBS) Shares Today. Their TP Given is $18.5

Caladrius Biosciences (NASDAQ:CLBS) Rating Reaffirmed

In an analyst note issued to investors and clients on Friday, 15 March, The Buy rating of Caladrius Biosciences (NASDAQ:CLBS) shares was maintained by Analysts at H.C. Wainwright, who now has a $18.5 target price per share on the stock. H.C. Wainwright’s target price per share indicates a possible upside of 378.04 % from the current price of the company.

The stock decreased 8.08% or $0.34 during the last trading session, reaching $3.87. About 18,631 shares traded. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has declined 15.79% since March 16, 2018 and is downtrending. It has underperformed by 20.16% the S&P500.

Analysts await Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report earnings on March, 28. They expect $-0.38 EPS, up 5.00 % or $0.02 from last year’s $-0.4 per share. After $-0.36 actual EPS reported by Caladrius Biosciences, Inc. for the previous quarter, Wall Street now forecasts 5.56 % negative EPS growth.

More notable recent Caladrius Biosciences, Inc. (NASDAQ:CLBS) news were published by: which released: “Mid-Day Market Update: Invacare Surges Following Strong Q4 Results; Motif Bio Shares Slide – Benzinga” on February 14, 2019, also with their article: “Caladrius Biosciences: Cheap With Catalysts On The Way – Seeking Alpha” published on September 24, 2018, published: “Mid-Morning Market Update: Markets Open Lower; Cisco Earnings Top Estimates – Benzinga” on February 14, 2019. More interesting news about Caladrius Biosciences, Inc. (NASDAQ:CLBS) were released by: and their article: “Caladrius Biosciences to Participate in Upcoming January Conferences – GlobeNewswire” published on January 07, 2019 as well as‘s news article titled: “52 Stocks Moving In Thursday’s Mid-Day Session – Benzinga” with publication date: February 14, 2019.

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.